Partner With Us NRI

Glenmark Life Sciences Ltd share Price

Company details

6M Return 52.73%
1Y Return 62.32%
Mkt Cap.(Cr) 7,568.49
Volume 215,520
Div Yield 6.81%
OI Chg %
Volume 215,520

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Glenmark Life Sciences announced Q1FY24 results:

  • GLS registered revenue from operations of Rs 5,785 million for Q1FY24, recording a strong growth of 18.1% YoY and a decline of 6.9% compared to the high base of Q4FY23.
  • Gross margins improved strongly in Q1FY24 trending at 57.1%, up 220 bps QoQ and 380 bps YoY; driven by lower input costs and a better product mix.
  • EBITDA for Q1FY24 was at Rs 1,950 million up 24.8% YoY.
  • EBITDA margins were at 33.7%, up 180 bps YoY driven by higher gross margin and offset by higher operating cost.
  • PAT was at Rs 1,355 million in Q1FY24, registering a growth of 24.6% YoY. PAT Margin for the quarter was at 23.4%, up 120 bps YoY.
  • R&D expenditure for Q1FY24 was at Rs 174 million, 3% of sales.
  • Capital expenditure for Q1FY24 was at Rs 354 million.
  • ROICE (adjusted for Cash and CWIP) was 35% for Q1FY24 and the Fixed assets turnover ratio at 2.7x.
  • Strong free cash generation of Rs 982 million during Q1FY24 leading to Cash & Cash Equivalents of Rs 3,820 million as on June 30 2023.

Commenting on the company’s performance Dr. Yasir Rawjee, MD & CEO, Glenmark Life Sciences said, “Our performance in the quarter was driven by Generic API and the CDMO businesses. Geographically, the US, Europe, ROW and India markets spearheaded this growth.

We remain focused on our strategic priorities of building capacities as well as strengthening our product pipeline. This coupled with an improved demand environment and supply situation will act as a catalyst for growth in the coming quarters.”

Commenting on the company’s performance Tushar Mistry, CFO, Glenmark Life Sciences said, “I am delighted to report continued growth momentum in Q1 with improved gross margins on the back of rationalisation in input cost and improved product mix. EBITDA and PAT margins improved due to better gross margins.

GLS generated strong free cash flow of Rs 98 crore during the quarter further strengthening the debt-free balance sheet.”


Result PDF

View Other Company Results


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Glenmark Life Sciences Ltd Stocks COMPARISION


Equity Capital: 2,138.21 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 15,612.36 -19,132.24
LAST 3M 53,075.98 -4,241.70
LAST 6M 58,662.39 138,824.89
LAST 12M 133,944.68 162,473.45
Glenmark Life Sciences Limited - Credit Rating

Oct 04, 2023 l NSE Announcement

Glenmark Life Sciences Limited - Public Announcement-Open Offer

Sep 28, 2023 l NSE Announcement

Date Action Type Ratio
Mar 24, 2023 Dividend 1050
Sep 15, 2022 Dividend 525
Nov 22, 2021 Dividend 525

Glenmark Life Sciences Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • The company was incorporated as `Zorg Laboratories Private Limited`, a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune ("RoC"). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to `Glenmark Life Sciences Private Limited` pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders` resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019. The company is primarily engaged in the business of development,manufacture and marketing of Active Pharmaceutical Ingredients(APIs). The company`s R&D facilities are located at Mahape,Ankleshwar and Dahej and manufacturing facilities are located at Ankleshwar,Dahej,Mohol and Kurkumbh. During the year 2018-19, the company allotted 4,50,090 Equity Shares of Rs. 10/- each on the conversion of loan given to Director. During the year, 15,00,000 equity shares of the face value of Rs. 10 each fully paid-up issued to Glenmark Pharmaceuticals Limited (Parent Company) pursuant to the Preferential Allotment. Subsequent to the quarter ended 30 June 2021, the company has completed the IPO of 21,022,222 equity shares comprising a fresh issue of 14,722,222 equity shares and offer for sale of 6,300,000 equity shares of face value of Rs 2 each at premium of Rs 718 per share aggregating to Rs 15,136 million. Pursuant to the IPO, the equity shares of the Company are listed on BSE Limited and National Stock Exchange of India Limited with effect from 06 August 2021. The Gross Debt comprising of Outstanding Purchase Consideration payable to the Parent Company was Rs 8,008.3 million as on 09 July 2021.The Company has repaid the whole of this remaining outstanding purchase consideration from the proceeds of the Fresh Issue pursuant to the IPO.

Registered Address

Plot No. 170-172 Chandramouli, Industrial Est.Mohol Bazarpeth, Solapur, Maharashtra, 413213

Tel : 91-2189-234456/234246
Email : complianceofficer:glenmarklifesciences.com
Website : http://www.glenmarklifesciences.com

KFin Techologies Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 543322
NSE Code : GLS
Book Closure Date (Month) :
BSE Group : B
ISIN : INE03Q201024

FAQ’s on Glenmark Life Sciences Ltd Shares

You can buy Glenmark Life Sciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glenmark Life Sciences Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Oct 04, 2023 03:51 PM the closing price of Glenmark Life Sciences Ltd was ₹ 617.70.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Oct 04, 2023 03:51 PM, the market cap of Glenmark Life Sciences Ltd stood at ₹ 7,568.49.

The latest PE ratio of Glenmark Life Sciences Ltd as of Oct 04, 2023 03:51 PM is 15.32

The latest PB ratio of Glenmark Life Sciences Ltd as of Oct 04, 2023 03:51 PM is 0.28

The 52-week high of Glenmark Life Sciences Ltd is ₹ 675.00 while the 52-week low is ₹ 370.00

Download Our App

market app
market app